Is there a less expensive replacement for Breo (fluticasone and vilanterol) for a patient with chronic obstructive pulmonary disease (COPD) or asthma?

Is There a Less Expensive Alternative to Breo for COPD or Asthma?

Yes, generic alternatives and other medication combinations can provide equivalent therapeutic benefit at lower cost, particularly for COPD patients who may not require the specific ICS/LABA combination that Breo provides.

Understanding Breo and Its Components

Breo Ellipta contains fluticasone furoate (an inhaled corticosteroid) and vilanterol (a long-acting beta-2 agonist), delivered once daily 1. While effective, several less expensive alternatives exist depending on your specific condition and severity.

Cost-Effective Alternatives by Disease and Severity

For Mild COPD

• Short-acting bronchodilators as needed are the most cost-effective first-line option 2, 3
• Use albuterol (short-acting beta-2 agonist) or ipratropium (anticholinergic) only when symptomatic, not on a scheduled basis 2
• If you have no symptoms, no drug treatment is required 3
• Avoid scheduled albuterol - this should never be used as maintenance therapy in stable COPD 2

For Moderate to Severe COPD

• Long-acting muscarinic antagonists (LAMAs) like tiotropium are preferred over ICS/LABA combinations and are generally less expensive 2
• LAMAs are more effective than LABAs in COPD and have greater effect on exacerbation reduction 2
• If monotherapy is insufficient, LAMA + LABA combination (without the corticosteroid component) is more cost-effective than triple therapy for most patients 2

When ICS/LABA Combinations Are Justified

Only add inhaled corticosteroids if BOTH criteria are met 4, 2:

• FEV1 < 50% predicted AND
• At least one exacerbation requiring oral corticosteroids or antibiotics within the last year 4

Generic ICS/LABA Alternatives to Breo

If you genuinely need an ICS/LABA combination:

• Fluticasone propionate/salmeterol (generic Advair) - twice daily dosing but significantly less expensive 5, 1
• Wixela Inhub - an FDA-approved generic equivalent of Advair Diskus, available in 100/50,250/50, and 500/50 mcg strengths 5
• Studies show fluticasone propionate/salmeterol 250/50 mcg twice daily has similar efficacy to fluticasone furoate/vilanterol (Breo) for pulmonary function 1

Practical Considerations for Cost Savings

Device Selection Matters for Cost

• Metered dose inhalers (MDIs) are the cheapest delivery device and should be tried first 2
• If you cannot use an MDI correctly (76% of COPD patients make important errors), then a dry powder inhaler is justified despite higher cost 2
• Always verify proper inhaler technique before switching devices or medications 2

Stepwise Approach to Minimize Cost

1. Start with as-needed short-acting bronchodilators for mild symptoms 2, 3
2. Escalate to LAMA monotherapy (like tiotropium) if symptoms require frequent rescue inhaler use 2
3. Add LABA to LAMA if monotherapy insufficient 2
4. Only add ICS if you meet the specific criteria above (severe disease with frequent exacerbations) 4, 2

Critical Warnings

• Beta-blocking agents (including eyedrop formulations) must be avoided in all COPD patients 3
• Do not use scheduled short-acting bronchodilators as maintenance therapy - this wastes money and provides no benefit over as-needed use 2
• Subjective improvement alone does not justify continued ICS use - you need objective spirometric improvement (FEV1 increase ≥200 mL AND ≥15% from baseline) 3

When Breo May Be Worth the Cost

Breo's once-daily dosing may justify higher cost if 1, 6:

• You have documented poor adherence to twice-daily regimens
• You meet criteria for ICS/LABA therapy based on disease severity
• You have failed or cannot tolerate generic alternatives

However, for most COPD patients, a stepwise approach starting with less expensive bronchodilators will provide adequate symptom control at substantially lower cost 2, 3.